Note: Descriptions are shown in the official language in which they were submitted.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
LIPOPHILIC DRUG DELIVERY VEHICLE AND METHODS OF USE
THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent
Application Serial
Nos. 60/447,508, filed February 14, 2003, and 60/508,035, filed October l,
2003, the
disclosures of both of which are incorporated herein by reference in their
entireties.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
[0002] This invention was made in part during work supported by grant no.
HL65159
from the National Institutes of Health. The government may have certain rights
in the
invention.
FIELD OF THE INVENTION
[0003] This application relates to compositions and methods for delivery of
bioactive
agents. In particular, the application relates to bioactive agent delivery
particles that
include a lipid binding polypeptide, a lipid bilayer, and a bioactive agent.
BACKGROUND OF THE INVENTION
[0004] Bioactive substances such as therapeutic agents, vaccine immunogens,
and
nutrients often cannot be administered in pure form, but must be incorporated
into
biocompatible formulations that enhance solubility of the bioactive material
and package it
in a suitable foim to achieve optimal beneficial effects while minimizing
undesirable side
effects. Efficient delivery of bioactive agents is often hindered by a short
clearance time of
an agent in the body, inefficient targeting to a site of action, or the nature
of the bioactive
agent itself, for example, poor solubility in aqueous media or hydrophobicity.
Thus, many
formulation strategies have been developed to improve delivery, including
controlled
release formulations, emulsions, and liposomal preparations.
[0005] Liposomal pharmaceutical delivery systems have been described.
Liposomes are
completely closed, spherical lipid bilayer membranes containing an entrapped
aqueous
volume. The lipid bilayer includes two lipid monolayers composed of lipids
having a
hydrophobic tail region and a hydrophilic head region. The structure of the
membrane
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
bilayer is such that the hydrophobic, nonpolar tails of the lipid molecules
orient toward the
center of the bilayer while the hydrophilic heads orient toward the aqueous
phases both on
the exterior and the interior of the liposome. The aqueous, hydrophilic core
region of a
liposome may include a dissolved bioactive substance.
[0006] Delivery of pharmaceutically useful hydrophobic substances is often
particularly
problematic because they are insoluble or poorly soluble in an aqueous
environment. For
hydrophobic compounds used as pharmaceuticals, direct injection may be
impossible or
highly problematic, resulting in such dangerous conditions as hemolysis,
phlebitis,
hypersensitivity, organ failure, and/or death. There is a need for improved
formulations for
hydrophobic bioactive substances that will promote stability in an aqueous
environment
and allow efficient delivery of such substances to a desired site of action.
BRIEF SUMMARY OF THE INVENTION
[0007] The invention provides compositions and methods for delivery of a
bioactive
agent to an individual.
[0008] In one aspect, the invention provides a bioactive agent delivery
particle that
includes a lipid binding polypeptide, a lipid bilayer with an interior that
includes a
hydrophobic region, and a bioactive agent associated with the hydrophobic
region of the
lipid bilayer. Bioactive agent delivery particles generally do not include a
hydrophilic or
aqueous core. '
[0009] Bioactive agent delivery particles include one or more bioactive agents
that
include at least one hydrophobic region and are incorporated into, or
associated with, the
hydrophobic interior of the lipid bilayer. The hydrophobic regions) of a
bioactive agent
are generally associated with hydrophobic surfaces in the interior of the
lipid bilayer, e.g.,
fatty acyl chains. In one embodiment, the bioactive agent is amphotericin B
(AmB). In
another embodiment, the bioactive agent is camptothecin.
[0010] Particles are typically disc shaped, with a diameter in the range of
about 7 to
about 29 nm.
[0011] Bioactive agent delivery particles include bilayer-forming lipids, for
example
phospholipids. In some embodiments, a bioactive agent delivery particle
includes both
bilayer-forming and non-bilayer-forming lipids. In some embodiments, the lipid
bilayer of
a bioactive agent delivery particle includes phospholipids. In one embodiment,
the
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
phospholipids incorporated into a delivery particle include
dimyristoylphosphatidylcholine
(DMPC) and dimyristoylphosphatidylglycerol (DMPG). In one embodiment, the
lipid
bilayer includes DMPC and DMPG in a 7:3 molar ratio.
[0012] In a preferred embodiment, the lipid binding polypeptide is an
apolipoprotein.
The predominant interaction between lipid binding polypeptides, e.g.,
apolipoprotein
molecules, and the lipid bilayer is generally a hydrophobic interaction
between residues on
a hydrophobic face of an amphipathic structure, e.g., an a-helix of the lipid
binding
polypeptide and fatty acyl chains of lipids on an exterior surface at the
perimeter of the
particle. Particles of the invention may include exchangeable and/or non-
exchangeable
apolipoproteins. In one embodiment, the lipid binding polypeptide is
Apolipoprotein A-I
(ApoA-I).
[0013] In some embodiments, particles are provided that include lipid binding
polypeptide molecules, e.g., apolipoprotein molecules, that have been modified
to increase
stability of the particle. In one embodiment, the modification includes
introduction of
cysteine residues to form intramolecular and/or intermolecular disulfide
bonds.
(0014] In another embodiment, particles are provided that include a chimeric
lipid
binding polypeptide molecule, e.g., a chimeric apolipoprotein molecule, with
one or more
bound functional moieties, for example one or more targeting moieties and/or
one or more
moieties having a desired biological activity, e.g., antimicrobial activity,
which may
augment or work in synergy with the activity of a bioactive agent incorporated
into the
delivery particle.
(0015] In another aspect, a pharmaceutical composition is provided that
includes a
bioactive agent delivery particle in a pharmaceutically acceptable carrier. A
method for
administering a bioactive agent to an individual is also provided, which
includes
administering a pharmaceutical composition containing bioactive agent delivery
particles in
a pharmaceutically acceptable carrier to the individual. In some embodiments,
a
therapeutically effective amount of the bioactive agent is administered in a
pharmaceutically acceptable carrier. In some embodiments, administration is
parenteral,
for example intravenous, intramuscular, intraperitoneal, transmucosal, or
intrathecal. In
other embodiments, particles are administered as an aerosol. In some
embodiments, the
bioactive agent is formulated for controlled release. In one embodiment, a
method is
provided for treating a fungal infection in an individual, including
administering a anti-
fungal agent, for example, AmB, incorporated into bioactive agent delivery
particles of the
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
invention, often in a therapeutically effective amount in a pharmaceutically
acceptable
carrier. In another embodiment, a method is provided for treating a tumor in
an individual,
including administering an anti-tumor agent, for example, camptothecin,
incorporated into
bioactive agent delivery particles of the invention, often in a
therapeutically effective
amount in a pharmaceutically acceptable carrier. In one embodiment, the
bioactive agent
delivery particles include a lipid binding polypeptide with an attached
vasoactive intestinal
peptide targeting moiety, and the tumor is a breast tumor. '
[0016] In a still fiu ther aspect, processes are provided for formulating
bioactive agent
delivery particles as described above. In one embodiment, the formulation
process includes
contacting a mixture that includes bilayer-forming lipids and a bioactive
agent to form a
lipid vesicle-bioactive agent mixture, and contacting the lipid vesicle-
bioactive agent
mixture with a lipid binding polypeptide. In another embodiment, the
formulation process
includes formation of a dispersion of pre-formed bilayer-containing lipid
vesicles to which
a bioactive agent, dissolved in an appropriate solvent, is added. Appropriate
solvents for
solubilizing a bioactive agent for this procedure include solvents with polar
or hydrophilic
character that are capable of solubilizing a bioactive agent to be
incorporated into a
delivery particle of the invention. Examples of suitable solvents include, but
are not
limited to, dimethylsulfoxide (DMSO) and dimethylformamide. To the
vesicle/bioactive
agent mixture, lipid binding polypeptides are added, followed by incubation,
sonication, or
both. In one embodiment, the bioactive agent incorporated into a delivery
particle by any
of the above processes is amphotericin B. In one embodiment, the amphotericin
B is
solubilized in DMSO. In another embodiment, the bioactive agent is
camptothecin. In one
embodiment, the camptothecin is solubilized in DMSO.
[0017] The invention includes bioactive agent delivery particles prepared
according to
any of the processes described above, and pharmaceutical compositions
including particles
prepared according to any of the above processes and a pharmaceutically
acceptable
carrier.
[0018] In another aspect, the invention provides kits including any of the
bioactive agent
delivery particles or pharmaceutical compositions described above, or delivery
particles
prepared by any of the above methods, and/or reagents for formulating the
particles and/or
instructions for use in a method for administering a bioactive agent to an
individual.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 depicts a LTV/Visible absorbance spectrum, from 250-450 nm, of
ApoA-
I-phospholipid particles without a bioactive agent, prepared as in Example 1:
[0020] Figure 2 depicts a UV/Visible absorbance spectrum, from 250-450 nm, of
ApoA-
I-phospholipid-AmB particles, prepared as in Example 1.
[0021] Figure 3 depicts a plot of fraction number versus protein concentration
for ApoA-
I-phospholipid-AmB particles after density gradient ultracentrifugation.
Particles were
prepared as described in Example 2 and adjusted to 1.3 g/ml density by the
addition of
KBr. The solution was centrifuged in a discontinuous gradient for 5 hours at
275,000 x g at
10°C. Following centrifugation, the tube contents were fractionated
from the top and the
protein content in each fraction determined.
[0022] Figure 4 depicts a native polyacrylamide gel electrophoresis (PAGE)
analysis of
ApoA-I-phospholipid particles, on a 4-20% acrylamide gradient slab gel.
Particles were
prepared with ApoA-I and two different lipid preparations, DMPC/DMPG or
palmitoyloleylphosphatidylcholine (POPC). The gel was stained with Coomassie
Blue.
Lane 1: ApoA-I POPC particles; Lane 2: ApoA-I-POPC-AmB particles; Lane 3: ApoA-
I-
DMPC/DMPG-AmB particles. The relative migration of size standards is shown on
the
left.
[0023] Figure 5 depicts a comparison of effects of different storage
conditions on the
size and structural integrity of Apoliprotein E N-terminal domain (ApoE3NT)-
DMPC/DMPG-AmB particle stability. Particles were isolated by density
ultracentrifugation and then subjected to electrophoresis on a native PAGE 4-
20% gradient
slab gel. The gel was stained with Amido Black. Lane 1: particles stored in
phosphate
buffer at 4°C for 24 hours; Lane 2: particles stored in phosphate
buffer at -20°C for 24
hours; Lane 3: particles lyophilized and frozen at -80°C for 24 hours,
and then redissolved
in H20. The relative migration of size standards is shown on the left.
[0024] Figure 6 schematically illustrates the shape and molecular organization
of a
bioactive agent delivery particle.
[0025] Figure 7 schematically illustrates chimeric lipid binding polypeptides
and their
incorporation into a bioactive agent delivery particle. The chimeric proteins
may include a
targeting moiety (Figure 7A) or a moiety with a desired biological activity
(Figure 7B).
Figure 7C schematically illustrates incorporation of the chimeric polypeptides
shown in
Figures 7A and 7B into a bioactive agent delivery particle.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
[0026] Figure 8 graphically depicts antifungal activity of AmB-containing
bioactive
agent delivery particles against Saccharomyces cerevisiae (S. cerevisiae) in
culture, as
described in Example 2.
[0027] Figure 9 is a freeze fracture electron micrograph of AmB-containing
bioactive
agent delivery particles, prepared as described in Example 10.
[0028] Figure 10 shows a comparison between the ability of ApoA-I-DMPC/DMPG-
AmB particles and AmBisome~ to inhibit growth of S. cerevisiae, as described
in Example
8.
[0029] Figure 11 shows, fluorescence spectral comparison between camptothecin
solubilized in SDS (Figure 11A) and camptothecin-containing bioactive agent
delivery
particles (Figure 11B), as described in Example 9.
[0030] Figure 12 depicts a UV/visible spectral comparison of AmB incorporation
into
lipid particles prepared as described in Example 7 (Figure 12A) and bioactive
agent
delivery particles prepared as described in Example 6 (Figure 12B).
[0031] Figure 13 is an illustration of an embodiment of a bioactive agent
delivery
particle preparation procedure.
[0032) Figure 14 shows changes in body weight of mice administered the
indicated
dosages of AmB-containing bioactive agent delivery particles as described in
Example 13.
[0033] Figure 15 shows serum levels of urea (Figure 15A), creatinine (Figure
15B),
aspartate aminotransferase (AST) (Figure 15C), and alanine aminotransferase
(Figure
15D) in mice that have been administered the indicated dosages of bioactive
agent delivery
particles as described in Example 13.
[0034] Figure 16 shows the survival rate of mice administered the indicated
treatment as
described in Example 14. AMB-ND: AmB-containing bioactive agent delivery
particles;
AmB: AmBisome; FLCZ: Fluconazole; ND: non-AmB-containing disc particles.
[0035] Figure 17 shows changes in body weight of mice administered the
indicated
treatment as described in Figure 14. AMB-ND: AmB-containing bioactive agent
delivery
particles; AmB: AmBisome; FLCZ: Fluconazole; ND: non-AmB-containing disc
particles.
[0036] Figure 18 shows tissue fungal burden in mice administered the indicated
treatment as described in Example 14. AMB-ND: AmB-containing bioactive agent
delivery particles; AmB: AmBisome; FLCZ: Fluconazole; ND: non-AmB-containing
disc
particles.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
[0037] Figure 19 shows the effect of apolipoprotein A-I on the light
scattering intensity
of AmB phospholipid vesicles. Two hundred micrograms of phospholipid (DMPC and
DMPG (7:3 molar ratio) and 50 micrograms AmB were dispersed into 20 mM sodium
phosphate, pH 7.4 by vortexing and incubated at 24 °C in the presence
and absence of
apolipoprotein. Sample right angle light scattering intensity was measured as
a function of
time in a Perkin-Elmer Model LSSOb luminescence spectrometer. The excitation
and
emission monochromators were set at 600 nm with a slit width of 4 nm. Curve A)
AmB
phospholipid vesicle preparation alone. Curve B) AmB phospholipid vesicle
preparation
plus 80 micrograms of apolipoprotein A-I.
DETAILED DESCRIPTION OF THE INVENTION
[0038] The invention provides compositions and methods for delivery of a
bioactive
agent to an individual. Delivery vehicles are provided in the form of a
bioactive agent
incorporated into a particle that includes a lipid binding polypeptide and a
lipid bilayer.
The interior of the particle includes a hydrophobic region of the lipid
bilayer that includes
hydrophobic portions of lipid molecules, e.g., fatty acyl chains of lipids, in
contrast to
liposomes, which include a wholly enclosed aqueous interior surrounded by
lipid
hydrophilic surfaces of a bilayer. The hydrophobic nature of the interior of a
particle of the
invention permits incorporation of hydrophobic molecules, for example, by
intercalation
between lipid molecules in the bilayer or sequestration into the hydrophobic
region
between leaflets of the bilayer. A bioactive agent that includes at least one
hydrophobic
region may be incorporated into the hydrophobic interior of the particle. As
used herein,
"incorporation" of a bioactive agent into the hydrophobic region of a lipid
bilayer refers to
solubilization into or association with a hydrophobic region or hydrophobic
portions of
lipid molecules of the bilayer, e.g., fatty acyl chains of lipids that form
the bilayer, or
intercalation with the fatty acyl chains.
[0039] The particles are generally disc shaped, with a diameter in the range
of about 7 to
29 nm, as determined by native pore limiting gradient gel electrophoresis, in
comparison
with standards of known Stokes' diameter, as described, for example, in
Blanche et al.
(1981) Biocl2im. Biophys. Acta. 665(3):408-19. In some embodiments, the
particles are
stable in solution and may be lyophilized for long term storage, followed by
reconstitution
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
in aqueous solution. The lipid binding polypeptide component defines the
boundary of the
discoidal bilayer and provides structure and stability to the particles.
[0040] Chimeric lipid binding polypeptide molecules (e.g., apolipoprotein
molecules) are
also provided and may be used to incorporate various additional functional
properties into
the delivery particles of the invention.
[0041] The particles may be administered to an individual to deliver a
bioactive agent to
the individual.
Bioactive Agent Delivery Particles
[0042] The invention provides a "particle" (also termed "delivery particle" or
"bioactive
agent delivery particle" herein) that includes one or more types of lipid
binding
polypeptide, a lipid bilayer comprising one or more types of bilayer-forming
lipid, and one
or more bioactive agents. In some embodiments, a delivery particle also
includes one or
more types of non-bilayer-forming lipid. Compositions including the particles
are also
provided. In one embodiment, a pharmaceutical composition is provided that
includes
delivery particles and a pharmaceutically acceptable carrier.
[0043] The interior of'a particle includes a hydrophobic region (e.g.,
comprised of lipid
fatty acyl chains). Particles of the invention typically do not comprise a
hydrophilic or
aqueous core. The particles are generally disc shaped, having a flat,
discoidal, roughly
circular lipid bilayer circumscribed by amphipathic a,-helices and/or (3-
sheets of the lipid
binding polypeptides, which are associated with hydrophobic surfaces of the
bilayer around
the periphery of the disc. An illustrative example of a disc shaped bioactive
agent delivery
particle of the invention is schematically depicted in Fig. 6.
[0044] Typically, the diameter of a disc shaped delivery particle is about 7
to about 29
nm, often about 10 to about 125 nm, often about 15 to about 20 nm. "Diameter"
refers to the
diameter of one of the roughly circular shaped faces of the disc.
Lipid BindingYPolypeptides
[0045] As used herein, a "lipid binding polypeptide" refers to any synthetic
or naturally
occurring peptide or protein that forms a stable interaction with lipid
surfaces and can
function to stabilize the lipid bilayer of a particle of the invention.
Particles may include
one or more types of lipid binding polypeptides, i.e., the lipid binding
polypeptides in a
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
single particle may be identical or may be composed of two or more different
polypeptide
sequences. The lipid binding polypeptides circumscribe the periphery of the
particle.
[0046] In some embodiments, lipid binding polypeptides useful for producing
delivery
particles in accordance with the invention include proteins having an amino
acid sequence
of a naturally occurring protein, or a fragment, natural variant, isoform,
analog, or chimeric
form thereof, proteins having a non-naturally occurring sequence, and proteins
or peptides
of any length that possess lipid binding properties consistent with known
apolipoproteins,
and may be purified from natural sources, produced recombinantly, or produced
synthetically. An analog of a naturally-occurring protein may be used. A lipid
binding
polypeptide may include one or more non-natural amino acids (e.g., D-amino
acids), amino
acid analogs, or a peptidomimetic structure, in which the peptide bond is
replaced by a
structure more resistant to metabolic degradation, or individual amino acids
are replaced by
analogous structures.
[0047] In a preferred embodiment, the lipid binding polypeptide is an
apolipoprotein.
Any apolipoprotein or fragment or analog thereof may be used that is capable
of
associating with a.lipid bilayer to form a disc shaped particle. Particles may
include
exchangeable, non-exchangeable, or a mixture of exchangeable and non-
exchangeable
apolipoprotein molecules.
[0048] Apolipoproteins generally possess a class A amphipathic a-helix
structural motif
(Segrest et al. (1994) Adv. Protein Chem. 45:303-369), and/or a (3-sheet
motif.
Apolipoproteins generally include a high content of a-helix secondary
structure with the
ability to bind to hydrophobic surfaces. A characteristic feature of these
proteins is their
ability to interact with certain lipid bilayer vesicles and to transform them
into disc-shaped
complexes (for a review, see Narayanaswami and Ryan (2000) Biochimica et
Biophysics
Acts 1483:15-36). Upon contact with lipids, the protein undergoes a
conformational
change, adapting its structure to accommodate lipid interaction.
[0049] Generally, the predominant interaction between apolipoproteins and the
lipid
bilayer in a particle is through a hydrophobic interaction between residues on
the
hydrophobic faces of amphipathic a-helices of apolipoprotein molecules and
hydrophobic
surfaces of lipids, for example, phospholipid fatty acyl chains, at the edge
of the bilayer at
the periphery of the bioactive agent delivery particle. An amphipathic a-helix
of an
apolipoprotein molecule includes both a hydrophobic surface in contact with a
hydrophobic
surface of the lipid bilayer at the periphery of the particle, and a
hydrophilic surface facing
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
the exterior of the particle and in contact with the aqueous environment when
the particle is
suspended in aqueous medium. In some embodiments, an apolipoprotein may
include an
amphipathic (3-sheet structure wherein hydrophobic residues of the (3-sheet
interact with
lipid hydrophobic surfaces at the periphery of the disc.
[0050] A bioactive agent delivery particle often comprises about 1 to about 10
molecules
of one or more types of apolipoprotein per particle. The amount of amphipathic
a-helix
contributed by the apolipoproteins in a particle is generally sufficient to
cover the otherwise
exposed hydrophobic surface of the lipid molecules located at the edge of the
disc shaped
lipid bilayer (i.e., the periphery of the particle). In one embodiment in
which the
apolipoprotein is human apolipoprotein A-I (ApoA-I) and the lipid bilayer
includes
palmitoyloleoylphosphatidylcholine, a particle comprises 2 ApoA-I molecules in
a ratio of
about 80 molecules of phospholipid to about 1 molecule of ApoA-I.
[0051] Examples of apolipoproteins which may be used for formation of the
delivery
particles of the invention include, but are not limited to, ApoA-I,
apolipoprotein E (ApoE),
and apolipophorin III (ApoIII), apolipoprotein A-IV (ApoA-IV), apolipoprotein
A-V
(ApoA-V), apolipoprotein C-I (ApoC-I), apolipoprotein C-II (ApoC-II),
apolipoprotein C-
III (ApoC-III), apolipoprotein D (ApoD)~ apolipoprotein A-II (ApoA-II),
apolipoproteirl B-
100 (ApoB-100), apolipoprotein J (ApoJ), apolipoprotein H (ApoH), or
fragments,°natural
variants, isoforms, analogs, or chimeric forms thereof. In some embodiments,
the
apolipoprotein is human ApoA-I. In other embodiments, the apolipoprotein is
the C-
terminal or N-terminal domain of apolipoprotein E3, or isoforms thereof. In
some
embodiments, the apolipoprotein includes a functional moiety that has been
attached either
synthetically or recombinantly, such as a targeting moiety or a moiety having
biological
activity, that is not intrinsic to the apolipoprotein (see, e.g., Fig. 7).
[0052] In some embodiments, an exchangeable apolipoprotein is used. An
"exchangeable apolipoprotein" may be displaced from a preformed discoidal
particle of the
invention by another protein or peptide with lipid binding affinity, without
destroying the
integrity of the particle. Exchangeable apolipoproteins include synthetic or
natural peptides
or proteins capable of forming a stable binding interaction with lipids. More
than a dozen
unique exchangeable apolipoproteins have been identified in both vertebrates
and
invertebrates (see, e.g., Narayanaswami and Ryan, supra).
[0053] In some embodiments, a non-exchangeable apolipoprotein is used. As used
herein, "non-exchangeable apolipoprotein" refers to a protein or peptide that
forms a stable
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
11
interaction with lipid surfaces and can function to stabilize the phospholipid
bilayer of
particles of the invention, but cannot be removed from the surface of the
particle without
destroying the intrinsic structure of the particle.
Bioactive Agents
[0054] The delivery particles include one or more bioactive agents. As used
herein,
"bioactive agent" refers to any compound or composition having biological,
including
therapeutic or diagnostic, activity. A bioactive agent may be a pharmaceutical
agent, drug,
compound, or composition that is useful in medical treatment, diagnosis, or
prophylaxis.
[0055] Bioactive agents incorporated into delivery particles as described
herein generally
include at least one hydrophobic (e.g., lipophilic) region capable of
associating with or
integrating into the hydrophobic portion of a lipid bilayer. In some
embodiments, at least a
portion of the bioactive agent is intercalated between lipid molecules in the
interior of the
delivery particle. Examples of bioactive agents that may be incorporated into
delivery
particles in accordance with the invention include, but are not limited to,
antibiotic or
antimicrobial (e.g., antibacterial, antifungal, and antiviral) agents,
antimetabolic agents,
antineoplastic agents, steroids, peptides, proteins, such as, for example,
cell receptor .
proteins, enzymes, hormones, and neurotransmitters, radiolabels such as
radioisotopes and
radioisotope-labeled compounds, fluorescent compounds, anesthetics, bioactive
lipids,
anticancer agents, anti-inflammatory agents, nutrients, antigens, pesticides,
insecticides,
herbicides, or a photosensitizing agent used in photodynamic therapy. In one
embodiment,
the bioactive agent is the anti-fungal agent AmB. In other embodiments, the
bioactive
agent is camptothecin, all-trans retinoic acid, annamycin, nystatin,
paclitaxel, docetaxel, or
etiopurpurins. Bioactive agents that include at least one hydrophobic region
are known in
the art and include, but are not limited to, ibuprofen, diazepam,
griseofulvin, cyclosporin,
cortisone, proleukin, etoposide, taxane, a-tocopherol, Vitamin E, Vitamin A,
and
lipopolysaccharides. See, for example, Kagkadis et al. (1996) PDA JPharm Sci
Tech
50(5):317-323; Dardel (1976) Anaesth Scand 20:221-24; Sweetana and Akers
(1996) PDA
JPharm Sci Tech 50(5):330-342; U.S. Pat. No. 6,45,373.
[0056] In some embodiments, a bioactive agent incorporated into a delivery
particle of
the invention is a non-polypeptide. In some embodiments, for administration to
an
individual, a bioactive agent and the delivery particle that includes the
bioactive agent are
substantially nonimmunogenic when administered to an individual.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
12
[0057] In some embodiments, a bioactive agent incorporated into a delivery
particle of
the invention exhibits improved solubility when compared to the solubility of
the bioactive
agent in an aqueous medium. Often, formulation into a delivery particle
results in
decreased turbidity of an aqueous composition comprising the bioactive agent.
This is
often reflected in an altered spectroscopic profile for the bioactive agent
upon formulation
into a delivery particle. A decrease in turbidity may be detected and/or
quantified by
measurement of optical density of a sample.
[0058] The invention provides a bioactive agent delivery particle comprising a
lipid
binding polypeptide, a lipid bilayer, and a bioactive agent, wherein the
interior of the lipid
bilayer comprises a hydrophobic region, wherein the bioactive agent is
associated with the
hydrophobic region of the lipid bilayer, and wherein the bioactive agent
delivery particle
comprises a bioactive agent with greater solubility in aqueous medium than the
bioactive
agent in aqueous medium alone (i. e., without formulation into a bioactive
agent delivery
particle). In one embodiment, AmB exhibits greater aqueous solubility in
delivery particles
than in aqueous medium. In another embodiment, camptothecin exhibits greater
aqueous
solubility in delivery particles than in aqueous medium.
[0059] The'invention also provides pharmaceutical compositions comprising
bioactive
agents with greater solubility by virtue of their incorporation into delivery
particles than in
aqueous medium without incorporation into delivery particles. In some
embodiments,
increased solubility can be observed by a decrease in precipitable material
upon
centrifugation, decreased light scattering, andlor decreased ability to filter
solid material.
In some embodiments, improved solubility of a bioactive agent permits its
administration at
a lower dosage than would be possible and/or efficacious without formulation
into a
delivery particle or administration in a different formulation, e.g., an
aqueous formulation,
a liposomal formulation, a colloid suspension, a cochleate, or a complex with
cyclodextrins. In some embodiments, the improved solubility of a bioactive
agent results
in lower toxicity and/or improved toxicity profile when administered to an
individual, such
as a mammalian individual, for example a human individual, than would be the
case if the
bioactive agent were administered without formulation into a delivery particle
or
administered in a different formulation, e.g., an aqueous formulation, a
liposomal
formulation, an aqueous formulation, a liposomal formulation, a colloid
suspension, a
cochleate, or a complex with cyclodextrins. In some embodiments, the improved
solubility
of a bioactive agent results in greater efficacy when administered to an
individual, such as a
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
13
mammalian individual for example a human individual, than would be the case if
the
bioactive agent were administered without formulation into a delivery particle
or
administered in a different formulation, e.g., an aqueous formulation, a
liposomal
formulation, an aqueous formulation, a liposomal formulation, a colloid
suspension, a
cochleate, or a~complex with cyclodextrins.
Lipid BilaYer
[0060] Particles of the invention include a lipid bilayer, with the generally
circular faces
of the disc comprising polar head groups facing away from the interior of the
particle, and
the interior of the particle (i. e., the space between the circular faces)
comprising a
hydrophobic region of the lipid bilayer that contains hydrophobic portions of
bilayer-
forming lipids) and other lipid components, if present. Hydrophobic surfaces
of the lipid
molecules at the edge of the bilayer (the surface at the periphery of the
bioactive agent
delivery particle) contact the lipid binding polypeptides of the particles, as
discussed above.
Particles may include one or more types of bilayer-forming lipids, or a
mixture of one or
more types of bilayer-forming and one or more types of non-bilayer-forming
lipids. As
used herein, "lipid" refers to a substance of biological or synthetic origin
that is soluble or
partiallysoluble in organic solvents or which partitions into a hydrophobic
environment
when present in aqueous phase.
[0061] Any bilayer-forming lipid that is capable of associating with a lipid
binding
polypeptide to form a disc shaped structure may be used in accordance with the
invention.
As used herein, "bilayer-forming lipid" refers to a lipid that is capable of
forming a lipid
bilayer with a hydrophobic interior and a hydrophilic exterior. Bilayer-
forming lipids
include, but are not limited to, phospholipids, sphingolipids, glycolipids,
alkylphospholipids, ether lipids, and plasmalogens. One type of bilayer-
forming lipid may
be used or a mixture of two or more types. In some embodiments, the lipid
bilayer includes
phospholipids. Examples of suitable phospholipids include, but are not limited
to, DMPC,
DMPG, POPC, dipalmitoylphosphatidylcholine (DPPC),
dipalmitoylphosphatidylserine
(DPPS), cardiolipin, dipalmitoylphosphatidylglycerol (DPPG),
distearoylphosphatidylglycerol (DSPG), egg yolk phosphatidylcholine (egg PC),
soy bean
phosphatidylcholine, phosphatidylinositol, phosphatidic acid, sphingomyelin,
and cationic
phospholipids. Examples of other suitable bilayer-forming lipids include
cationic lipids
and glycolipids. In one embodiment, the particles include a phospholipid
bilayer of DMPC
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
14
and DMPG, often in a molar ratio of about 7:3. In another embodiment, the
particles
include a phospholipid bilayer of POPC. In some embodiments, mixtures of
bilayer-
forming lipids may be used in molar ratios of any of at least about 1:100,
1:50, 1:20, 1:10,
1:5, 3:7, 1:2, or 1:1.
[0062] Particles may also include lipids that are not bilayer-forming lipids.
Such lipids
include, but are not limited to, cholesterol, cardiolipin,
phosphatidylethanolamine (this lipid
may form bilayers under certain circumstances), oxysterols, plant sterols,
ergosterol,
sitosterol, cationic lipids, cerebrosides, sphingosine, ceramide,
diacylglycerol,
monoacylglycerol, triacylglycerol, gangliosides, ether lipids,
alkylphospholipids,
plasmalogens, prostaglandins, and lysophospholipids. In some embodiments, a
lipid used
for preparation of a delivery particle may include one or more bound
functional moieties,
such as targeting moieties, bioactive agents, or tags for purification or
detection.
Clzimeric lipid binding polypeptides
[0063] The invention provides chimeric lipid binding polypeptides, which may
be used to
.prepare the delivery particles described above. A chimeric lipid binding
polypeptide may .
include one or more attached "functional moieties," such as for example, one
or more
targeting moieties, a moiety having a desired biological activity, an affinity
tag to assist
with purification, and/or a reporter molecule for characterization or
localization studies.
An attached moiety with biological activity may have an activity that is
capable of
augmenting and/or synergizing with the biological activity of a bioactive
agent
incorporated into the delivery particle. For example, a moiety with biological
activity may
have antimicrobial (for example, antifungal, antibacterial, anti-protozoal,
bacteriostatic,
fungistatic, or antiviral) activity. In one embodiment, an attached functional
moiety of a
chimeric lipid binding polypeptide is not in contact with hydrophobic surfaces
of the lipid
bilayer when the lipid binding polypeptide is incorporated into a bioactive
agent delivery
particle. In another embodiment, an attached functional moiety is in contact
with
hydrophobic surfaces of the lipid bilayer when the lipid binding polypeptide
is incorporated
into a bioactive agent delivery particle. In some embodiments, a functional
moiety of a
chimeric lipid binding polypeptide may be intrinsic to a natural protein. In
some
embodiments, a chimeric lipid binding polypeptide includes a ligand or
sequence
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
recognized by or capable of interaction with a cell surface receptor or other
cell surface
moiety.
[0064] In some embodiments, a chimeric lipid binding polypeptide is a chimeric
apolipoprotein. In one embodiment, a chimeric apolipoprotein includes a
targeting moiety
that is not intrinsic to the native apolipoprotein, such as for example, S
cerevisiae a-mating
factor peptide, folic acid, transferrin, or lactoferrin. In another
embodiment, a chimeric
apolipoprotein includes a moiety with a desired biological activity that
augments and/or
synergizes with the activity of a bioactive agent incorporated into the
delivery particle, such
as for example, histatin-5, magainin peptide, mellitin, defensin, colicin, N-
terminal
lactoferrin peptide, echinocandin, hepcidin, bactenicin, or cyclosporine. In
one
embodiment, a chimeric lipid binding polypeptide may include a functional
moiety intrinsic
to an apolipoprotein. One example of an apolipoprotein intrinsic functional
moiety is the
intrinsic targeting moiety formed approximately by amino acids 130-150 of
human ApoE,
which comprises the receptor binding region recognized by members of the low
density
lipoprotein receptor family. Other examples of apolipoprotein intrinsic
functional moieties
include the region of ApoB-100 that interacts with the low density lipoprotein
receptor and
the region of ApoA-I that interacts with scavenger receptor type B 1. In other
embodiments,
a functional moiety may be added synthetically or recombinantly o produce a
chimeric '~
lipid binding polypeptide.
[0065] As used herein, "chimeric" refers to two or more molecules that are
capable of
existing separately and are joined together to form a single molecule having
the desired
functionality of all of its constituent molecules. The constituent molecules
of a chimeric
molecule may be joined synthetically by chemical conjugation or, where the
constituent
molecules are all polypeptides or analogs thereof, polynucleotides encoding
the
polypeptides may be fused together recombinantly such that a single continuous
polypeptide is expressed. Such a chimeric molecule is termed a fusion protein.
A "fusion
protein" is a chimeric molecule in which the constituent molecules are all
polypeptides and
are attached (fused) to each other such that the chimeric molecule forms a
continuous
single chain. The various constituents can be directly attached to each other
or can be
coupled through one or more linkers.
[0066] A "linker" or "spacer" as used herein in reference to a chimeric
molecule refers to
any molecule that links or joins the constituent molecules of the chimeric
molecule. A
number of linker molecules are commercially available, for example from Pierce
Chemical
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
16
Company, Rockford Illinois. Suitable linkers are well known to those of skill
in the art and
include, but are not limited to, straight or branched-chain carbon linkers,
heterocyclic
carbon linkers, or peptide linkers. Where the chimeric molecule is a fusion
protein, the
linker may be a peptide that joins the proteins comprising a fusion protein.
Although a
spacer generally has no specific biological activity other than to join the
proteins or to
preserve some minimum distance or other spatial relationship between them, the
constituent amino acids of a peptide spacer may be selected to influence some
property of
the molecule such as the folding, net charge, or hydrophobicity.
[0067] In some embodiments, a chimeric lipid binding polypeptide, such as a
chimeric
apolipoprotein, is prepared by chemically conjugating the lipid binding
polypeptide
molecule and the functional moiety to be attached. Means of chemically
conjugating
molecules are well known to those of skill in the art. Such means will vary
according to
the structure of the moiety to be attached, but will be readily ascertainable
to those of skill
in the art.
[0068] Polypeptides typically contain a variety of functional groups, e.g.,
carboxylic acid
(-COOH), free amino (-NH2), or sulfhydryl (-SH) groups, that are available
for°reaction
with ~a suitable functional group on the functional moiety or on a. linker to
bind. the moiety
. thereto. A functional moiety may be attached at the N-terminus, the C-
terminus, or to a
functional group on an interior residue (i. e., a residue at a position
intermediate between the
N- and C- termini) of an apolipoprotein molecule. Alternatively, the
apolipoprotein and/or
the moiety to be tagged can be derivatized to expose or attach additional
reactive functional
groups.
[0069] In some embodiments, lipid binding polypeptide fusion proteins that
include a
polypeptide functional moiety are synthesized using recombinant expression
systems.
Typically, this involves creating a nucleic acid (e.g., DNA) sequence that
encodes the lipid
binding polypeptide and the functional moiety such that the two polypeptides
will be in
frame when expressed, placing the DNA under the control of a promoter,
expressing the
protein in a host cell, and isolating the expressed protein.
[0070] . Lipid binding polypeptide sequences and sequences encoding functional
moieties
as described herein may be cloned, or amplified by in vitro methods, such as,
for example,
the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the
transcription-
based amplification system (TAS), or the self sustained sequence replication
system (SSR).
A wide variety of cloning and in vitro amplification methodologies are well
known to
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
17
persons of skill. Examples of techniques sufficient to direct persons of skill
through in vitro
amplification methods are found for example, in Mullis et al., (1987) U.S.
Patent No.
4,683,202; PCR Protocols A Guide to Methods arid Applications (Innis et al.
eds)
Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October
1,
1990) C&EN 36-47; The Journal OfNIHResearch (1991) 3: 81-94; (Kwon et al.
(1989)
Proc. Natl. Acad. Sci. LISA 86: 1173; Guatelli et al. (1990) Proc. Natl. Acad.
Sci. USA 87,
1874; Lomell et al. (1989) J. Clir~. Chem., 35: 1826; Landegren et al., (1988)
Science, 241:
1077-1080; Van Brunt (1990) Biotechnology, 8: 291-294; Wu and Wallace, (1989)
Gene,
4: 560; and Barringer et al. (1990) Gene, 89: 117.
[0071] In addition, DNA encoding desired fusion protein sequences may be
prepared
synthetically using methods that are well known to those of skill in the art,
including, for
example, direct chemical synthesis by methods such as the phosphotriester
method of
Naxang et al. (1979) Meth. Enzymol. 68: 90-99, the phosphodiester method of
Brown et
al.(1979) Meth. Enzymol. 68: 109-151, the diethylphosphoramidite method of
Beaucage et
al. (1981) Tetra. Lett., 22: 1859-1862, or the solid support method of U.S.
Patent No.
4,458,066. - w '
[0072] . A nucleic acid encoding a chimeric lipid binding polypeptide fusion
polypeptide
can be incorporated into a recombinant expression vector in a form suitable
for expression
in a host cell. As used herein, an "expression vector" is a nucleic acid
which, when
introduced into an appropriate host cell, can be transcribed and translated
into a
polypeptide. The vector may also include regulatory sequences such as
promoters,
enhancers, or other expression control elements (e.g., polyadenylation
signals). Such
regulatory sequences are known to those skilled in the art (see, e.g., Goeddel
(1990) Gene
Expression Technology: Meth. Enzymol. 185, Academic Press, San Diego, CA;
Berger and
Kimmel, Guide to Molecular Clohir~g Techniques, Methods ih Er~zymology 152
Academic
Press, Inc., San Diego, CA; Sambrook et al. (1989) Molecular Cloning - A
Laboratory
Manual (2r~d ed.) Yol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor
Press, NY,
etc. ).
[0073] In some embodiments, a recombinant expression vector for production of
a
chimeric lipid binding polypeptide is a plasmid or cosmid. In other
embodiments, the
expression vector is a virus, or portion thereof, that allows for expression
of a protein
encoded by the nucleic acid introduced into the viral nucleic acid. For
example, replication
defective retroviruses, adenoviruses and adeno-associated viruses can be used.
Expression
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
18
vectors may be derived from bacteriophage, including all DNA and RNA phage
(e.g.,
cosmids), or viral vectors derived from all eukaryotic viruses, such as
baculoviruses and
retroviruses, adenoviruses and adeno-associated viruses, Herpes viruses,
Vaccinia viruses
and all single-stranded, double-stranded, and partially double-stranded DNA
viruses, all
positive and negative stranded RNA viruses, and replication defective
retroviruses.
Another example of an expression vector is a yeast artificial chromosome
(YAC), which
contains both a centromere and two telomeres, allowing YACs to replicate as
small linear
chromosomes. Another example is a bacterial artificial chromosome (BAC).
[0074] The chimeric lipid binding polypeptide fusion proteins of this
invention can be
expressed in a host cell. As used herein, the term "host cell" refers to any
cell or cell line
into which a recombinant expression vector for production of a chimeric
apolipoprotein
fusion protein, as described above, may be transfected for expression. Host
cells include
progeny of a single host cell, and the progeny may not necessarily be
completely identical
(in morphology or in total genomic DNA complement) to the original paxent cell
due to
natural, accidental, or deliberate mutation. A host cell includes cells
transfected or
transformed in vivo with an expression vector as described above. Suitable
host cells
r
include, but are not limited to, bacterial.cells (e.g. E. coli), fungal cells
(e.g., S. cerevisiae),
invertebrate cells (e.g. insect cells such as SF9 cells), and vertebrate cells
including '
mammalian cells.
[0075] An expression vector encoding a chimeric lipid binding polypeptide
fusion
protein can be transfected into a host cell using standard techniques.
"Transfection" or
"transformation" refers to the insertion of an exogenous polynucleotide into a
host cell.
The exogenous polynucleotide may be maintained as a non-integrated vector,
such as for
example a plasmid, or alternatively may be integrated into the host cell
genome. Examples
of transfection techniques include, but are not limited to, calcium phosphate
co-
precipitation, DEAE-dextran-mediated transfection, lipofection,
electroporation and
microinjection. Suitable methods for transfecting host cells can be found in
Sambrook et
al. (1989) Molecular Cloning: A Labof~atory Manual, 2nd Edition, Cold Spring
Harbor
Laboratory press, and other laboratory textbooks. Nucleic acid can also be
transferred into
cells via a delivery mechanism suitable for introduction of nucleic acid into
cells in vivo,
such as via a retroviral vector (see e.g., Ferry et al. (1991) Proc. Natl.
Acad. Sci., USA, 88:
8377-8381; and Kay et al. (1992) Human Gene Therapy 3: 641-647), an adenoviral
vector
(see, e.g., Rosenfeld (1992) Cell 68: 143-155; and Herz and Gerard (1993)
Pr~oc. Natl.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
19
Acad. Sci., USA, 90:2812-2816), receptor-mediated DNA uptake (see e.g., Wu,
and Wu
(1988) J. Biol. Chem. 263: 14621; Wilson et al. (1992) J. Biol. Chem. 267: 963-
967; and
U.S. Pat. No. 5,166,320), direct injection of DNA (see, e.g., Acsadi et al.
(1991) Nature,
332: 815-818; and Wolff et al. (1990) Science 247:1465-1468) or particle
bombardment
(biolistics) (see e.g., Cheng et al. (1993) Proc. Natl. Acad. Sci., USA,
90:4455-4459; and
Zelenin et al. (1993) FEBSLetts. 315: 29-32).
[0076] Once expressed, the chimeric lipid binding polypeptides may be purified
according to standard procedures of the art, including, but not limited to
affinity
purification, ammonium sulfate precipitation, ion exchange chromatography, or
gel
electrophoresis.
[0077] In some embodiments, a chimeric lipid binding polypeptide may be
produced
using a cell free expression system or via solid-state peptide synthesis.
Modified lipid binding polypeptides
[0078] In some embodiments of the invention, a lipid binding polypeptide
is.provided
that has been modified such that when the polypeptide is incorporated into a
bioactive
agent delivery particle as described above, the modification will increase
stability of the
particle. or confer targeting ability. In some embodiments, the modification
permits the
lipid binding polypeptides of a particle to stabilize the particle's disc
shaped structure or
conformation. In one embodiment, the modification includes introduction of
cysteine
residues into apolipoprotein molecules to permit formation of intramolecular
or
intermolecular disulfide bonds, e.g., by site-directed mutagenesis. In another
embodiment,
a chemical crosslinking agent is used to form intermolecular links between
apolipoprotein
molecules to enhance stability of the particles. Intermolecular crosslinking
prevents or
reduces dissociation of apolipoprotein molecules from the particles andlor
prevents
displacement by apolipoprotein molecules within an individual to whom the
particles are
administered.
[0079] In other embodiments, a lipid binding polypeptide is modified either by
chemical
derivatization of one or more amino acid residues or by site directed
mutagenesis, to confer
targeting ability to or recognition by a cell surface receptor.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
Delivery system for delivery of a bioactive agent to an individual
[0080] The invention provides a delivery system for delivery of a bioactive
agent to an
individual, comprising bioactive agent delivery particles as described above
and a carrier,
optionally a pharmaceutically acceptable carrier. In some embodiments, the
delivery
system comprises an effective amount of the bioactive agent.
[0081] As used herein, "individual" refers to any prokaryote or eukaryote to
which one
desires to deliver a bioactive agent. In some embodiments, the individual is a
prokaryote
such as a bacterium. In other embodiments, the individual is a eukaryote, such
as a fungus,
a plant, an invertebrate animal, such as an insect, or a vertebrate animal. In
some
embodiments, the individual is a vertebrate, such as a human, a nonhuman
primate, an
experimental animal, such as a mouse or rat, a pet animal, such as a cat or
dog, or a farm
animal, such as a horse, sheep, cow, or pig, a bird (i.e., avian individual),
or a reptile (i.e.,
reptilian individual).
[0082] In some embodiments, delivery particles are formulated in a suitable
carrier for
administration to an individual. As used herein, " carrier" refers to a
relatively 'inert
substance that facilitates administration of a bioactive agent. For example, a
carrier can
give form or consistency to the composition or can act as a diluent.
"Pharmaceutically
acceptable carriers" refer to carriers that are biocompatible (i.e., not toxic
to the host) and
suitable for a particular route of administration for a pharmacologically
effective substance.
Suitable pharmaceutically acceptable carriers include but are not limited to
stabilizing
agents, wetting and emulsifying agents, salts for varying osmolarity,
encapsulating agents,
buffers, and skin penetration enhancers. Examples of pharmaceutically
acceptable carriers
are described in Remington's Pharmaceutical Sciences (Alfonso R. Gennaro, ed.,
18th
edition, 1990).
[0083] As used herein, "effective amount" refers to an amount of a bioactive
agent
sufficient to effect desired results. A "therapeutically effective amount" or
"therapeutic
dose" refers to an amount of a bioactive agent sufficient to effect beneficial
clinical results,
such as for example reduction or alleviation of a symptom of a disease,
reduction or
alleviation of a fungal or bacterial infection, etc.
[0084] In some embodiments, the delivery system is a pharmaceutical
composition
comprising a bioactive agent delivery particle and a pharmaceutically
acceptable carrier. In
some embodiments, the pharmaceutical composition comprises a bioactive agent
delivery
particle that contains a non-polypeptide bioactive agent and a
pharmaceutically acceptable
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
21
carrier. In some embodiments, the bioactive agent delivery particle and the
bioactive agent
are non-immunogenic when administered to an individual. Immunogenicity may be
measured by methods that are well known in the art. For example,
immunogenicity may be
assessed by an ELISA method, for example by probing serum from an individual
to whom
bioactive agent delivery particles have been administered for antibody binding
to
equivalent bioactive agent delivery particles bound to an immunosorbent plate.
[0085] In some embodiments, the invention provides a pharmaceutical
composition
comprising a bioactive agent delivery particle, wherein the bioactive agent
exhibits greater
solubility in aqueous medium by virtue of its incorporation into the delivery
particle than
the bioactive agent in aqueous medium without incorporation into the delivery
particle. In
some embodiments, the invention provides a pharmaceutical composition
comprising a
bioactive agent delivery particle, wherein the bioactive agent exhibits lower
toxicity and/or
an improved toxicity profile when administered to an individual, such as a
mammalian
individual, for example a human individual, than the bioactive agent without
formulation
into the bioactive'agent delivery particle or administered in a different
formulation, for
example an aqueous formulation, a liposomal formulation, a colloid suspension,
a .
cochleate, or a complex with cyclodextrins. In some.embodiments, the invention
provides :-
a pharmaceutical. composition comprising a bioactive agent deliveryparticle,
wherein the
bioactive agent exhibits improved efficacy in treating a condition, for
example an infection,
such as a bacterial or fungal infection, a disease condition, a tumor, etc.,
than the bioactive
agent without formulation into the bioactive agent delivery particle or
administered in a
different formulation, for example an aqueous formulation, a liposomal
formulation, a
colloid suspension, a cochleate, or a complex with cyclodextrins. In some
embodiments, a
bioactive agent with improved solubility, toxicity profile, and/or efficacy is
AmB. In
another embodiment, a bioactive agent with improved solubility, toxicity
profile, and/or
efficacy is camptothecin.
Methods of use
[0086] The invention provides methods for administering a bioactive agent to
an
individual. The methods of the invention include administering a delivery
particle as
described above that includes a lipid binding polypeptide, a lipid bilayer,
and a bioactive
agent, wherein the interior of the particle includes hydrophobic surfaces of
the lipid bilayer.
Optionally, a therapeutically effective amount of the particles is
administered, optionally in
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
22
a pharmaceutically acceptable carrier. Generally, the particles are disc
shaped, with a
diameter of about 7 to about 29 nm, as measured by native pore limiting
gradient gel
electrophoresis. Typically, the bioactive agent includes at least one
hydrophobic region,
which may be integrated into a hydrophobic region of the lipid bilayer.
[0087] The route of administration may vary according to the nature of the
bioactive
agent to be administered, the individual, or the condition to be treated.
Where the
individual is a mammal, generally administration is parenteral. Routes of
administration
include, but are not limited to, intravenous, intramuscular, intraperitoneal,
subcutaneous,
transmucosal, nasal, intrathecal, topical, and transdermal. In one embodiment,
the particles
are administered as an aerosol. Delivery particles may be formulated in a
pharmaceutically
acceptable form for administration to an individual, optionally in a
pharmaceutically
acceptable Garner or excipient. The invention provides pharmaceutical
compositions in the
form of delivery particles in a solution for parenteral administration. For
preparing such
compositions, methods well known in the art may be used, and any
pharmaceutically
acceptable carriers, diluents, excipients, or other additives normally used in
the art may be
used.
[0088] The delivery particles of the present invention can be made into
pharmaceutical
compositions by combination with appropriate medical carriers or diluents. For
example;
the delivery particles can be solubilized in solvents commonly used in the
preparation of
injectable solutions, such as for example, physiological saline, water, or
aqueous dextrose.
Other suitable pharmaceutical carriers and their formulations are described in
Remington's
Pharmaceutical Sciences, supra. Such formulations may be made up in sterile
vials
containing delivery particles and optionally an excipient in a dry powder or
lyophilized
powder form. Prior to use, the physiologically acceptable diluent is added and
the solution
withdrawn via syringe for administration to an individual.
[0089] Delivery particles may also be formulated for controlled release. As
used herein,
"controlled release" refers to release of a bioactive agent from a formulation
at a rate that
the blood concentration of the agent in an individual is maintained within the
therapeutic
range for an extended duration, over a time period on the order of hours,
days, weeks, or
longer. Delivery particles may be formulated in a bioerodible or
nonbioerodible controlled
matrix, a number of which are well known in the art. A controlled release
matrix may
include a synthetic polymer or copolymer, for example in the form of a
hydrogel.
Examples of such polymers include polyesters, polyorthoesters, polyanhydrides,
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
23
polysaccharides, poly(phosphoesters), polyamides, polyurethanes,
poly(imidocarbonates)
and poly(phosphazenes), and poly-lactide-co-glycolide (PLGA), a copolymer of
poly(lactic
acid) and poly(glycolic acid). Collagen, albumin, and fibrinogen containing
materials may
also be used.
[0090] Delivery particles may be administered according to the methods
described herein
to treat a number of conditions including, but not limited to, bacterial
infections, fungal
infections, disease conditions, metabolic disorders, or as a prophylactic
medication, for
example to prevent a bacterial or fungal infection (e.g., pre- or post-
surgically). Delivery
particles may be used, for example, to deliver an anti-tumor agent (e.g.,
chemotherapeutic
agent, radionuclide) to a tumor. In one embodiment, the lipid binding
polypeptide includes
a moiety that targets the particle to a particular tumor. Delivery particles
may also be used
for administration of nutraceutical substances, i.e., a food or dietary
supplement that
provides health benefits. In some embodiments, delivery particles are co-
administered with
other conventional therapies, for example, as part of a multiple drug
"cocktail," or in
combination with one or more orally administered agents, for example, for
treatment of a
fungal infection. Delivery particles may also be administered as insecticides
or herbicides.
[0091] ' In one aspect, the invention provides a method for treating a fungal
infection in an
individual. The method includes administering a therapeutically effective
amount.of an
anti-fungal agent in a pharmaceutically acceptable carrier to the individual,
wherein the
anti-fungal agent is incorporated into a particle that includes a lipid
binding polypeptide
and a lipid bilayer, wherein the interior of the lipid bilayer is hydrophobic.
In one
embodiment, the anti-fungal agent is AmB, incorporated into the hydrophobic
interior of
the lipid bilayer. In some embodiments, the lipid binding polypeptide is a
chimeric protein
that includes a targeting moiety and/or a moiety with biological activity. In
one
embodiment, the lipid binding polypeptide includes the targeting moiety yeast
a-mating
factor peptide. In another embodiment, the lipid binding polypeptide includes
the anti-
microbial peptide histatin 5.
[0092] In another aspect, the invention provides a method for treating a tumor
in an
individual. The method includes administering a therapeutically effective
amount of a
chemotherapeutic agent in bioactive agent delivery particles as described
above, in a
pharmaceutically acceptable carrier. In one embodiment, the chemotherapeutic
agent is
camptothecin. A lipid binding polypeptide component of the delivery particles
may
include a targeting moiety to target the particles to tumor cells. In one
embodiment,
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
24
vasoactive intestinal peptide (VIP) is attached to the lipid binding
polypeptide. Since
breast cancer cells often overexpress the VIP receptor, in one embodiment,
bioactive agent
delivery particles comprising camptothecin and lipid binding polypeptide-VIP
chimeras are
used in a method of treatment for breast cancer.
Targeting
[0093] A delivery particle of the invention may include a targeting
functionality, for
example to target the particles to a particular cell or tissue type, or to the
infectious agent
itself. In some embodiments, the particle includes a targeting moiety attached
to a lipid
binding polypeptide or lipid component. In some embodiments, the bioactive
agent that is
incorporated into the particle has a targeting capability.
[0094] In some embodiments, by engineering receptor recognition properties
into a lipid
binding polypeptide, such as an apolipoprotein molecule, the particles can be
targeted to a
specific cell surface receptor. For example, bioactive agent delivery
particles may be
targeted to a particular cell type known to harbor a particular type of
infectious agent, for
example by modifying the lipid binding polypeptide component of the particles
to render it
capable of interacting with a receptor on the surface of the cell type being
targeted.
[0095] In one aspect, a receptor-mediated targeting strategy may be used to
deliver
antileishmanial agents to macrophages, which are the primary site of infection
for protozoal
parasites from the genus Leishmania. Examples of such species include
Leishmania major,
Leishmania donovani, and Leishmania braziliensis. Bioactive agent delivery
particles
containing an antileishmanial agent may be targeted to macrophages by altering
the lipid
binding polypeptide component of the particles to confer recognition by the
macrophage
endocytic class A scavenger receptor (SR-A). For example, an apolipoprotein
which has
been chemically or genetically modified to interact with SR-A may be
incorporated into
delivery particles that contain one or more bioactive agents that are
effective against
Leishma~cia species, such as, for example, AmB, a pentavalent antimonial,
andlor
hexadecylphosphocholine. Targeting of delivery particles that contain an
antileishmanial
agent specifically to macrophages may be used as a means of inhibiting the
growth and
proliferation of Leishmania spp.
[0096] In one embodiment an SR-A targeted bioactive agent delivery particle
containing
AmB is administered to an individual in need of treatment for a leishmanial
infection. In
another embodiment, another antileishmanial agent, such as
hexadecylphosphocholine is
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
administered prior, concurrently, or subsequent to treatment with the AmB
containing-
particles.
[0097] In some embodiments, targeting is achieved by modifying a lipid binding
polypeptide, such as an apolipoprotein, to be incorporated into the bioactive
agent delivery
particle, thereby conferring SR-A binding ability to the particle. In some
embodiments,
targeting is achieved by altering the charge density of the lipid binding
polypeptide by
chemically modifying one or more lysine residues, for example with
malondialdehyde,
malefic anhydride, or acetic anhydride at alkaline pH (see, e.g., Goldstein et
al. (1979) Proc.
Natl. Acad. Sci. 98:241-260). In one embodiment, Apo B-100 or a truncated form
thereof,
such as the N-terminal 17% of ApoB-100 (residues 1-782 of apoB-17), is
modified by
reaction with malondialdehyde. In other embodiments, an apolipoprotein
molecule, such as
any of the apolipoproteins described herein, may also be chemically modified
by, for
example acetylation or maleylation, and incorporated into a bioactive agent
delivery
particle containing an antileishmanial agent.
[0098] In other embodiments, SR-A binding ability is conferred to a delivery
particle by
modifying the lipid binding polypeptide by si"te, directed mutagenesis to
replace one or
more positively chaxged amino acids with a neutral or negatively charged amino
acid.
[0099] In other embodiments, SR-A recognition is conferred by preparing a
chimeric
lipid binding polypeptide that includes an N- or C-terminal extension having a
ligand
recognized by SR-A or an amino acid sequence with a high concentration of
negatively
charged residues. A negatively charged polypeptide extension would not be
attracted to the
lipid surface of the bioactive agent delivery particle, thereby rendering it
more accessible to
the ligand binding site of the receptor.
Methods for preparing bioactive agent delivery particles
[00100] The invention provides methods for formulating a bioactive agent
delivery
particle. In one embodiment, a process is provided that includes adding lipid
binding
polypeptide molecules to a mixture that includes bilayer-forming lipids and
bioactive agent
molecules.
[00101] In some embodiments, the lipid-bioactive agent mixture also includes a
detergent,
such as for example sodium cholate, cholic acid, or octyl glucoside, and the
process further
includes removing the detergent after the lipid binding polypeptide has been
added.
Typically, the detergent is removed by dialysis or gel filtration. In one
embodiment, the
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
26
process includes combining bilayer-forming lipids and bioactive agent
molecules in a
solvent to form a-bioactive agent mixture, drying the mixture to remove the
solvent (e.g.,
under a stream of NZ and/or by lyophilization), contacting the dried mixture
with a solution
that includes a detergent to form a lipid-bioactive agent-detergent mixture,
adding lipid
binding polypeptide molecules to this mixture, and then removing the
detergent.
[00102] In some embodiments, the particles are prepared using a microfluidizer
processor.
This procedure employs high pressure, forcing the components together in a
reaction
chamber.
[00103] In some embodiments, the particles are prepared by incubation of a
suspension of
lipid vesicles containing a bioactive agent in the presence of a lipid binding
polypeptide,
such as an apolipoprotein. In one embodiment, the suspension is sonicated.
[00104] In other embodiments, delivery particles are prepared from a pre-
formed vesicle
dispersion. Lipids, e.g., phospholipids, are hydrated with buffer and
dispersed by agitation
or sonication. To the dispersion of lipid bilayer vesicles, solubilized
bioactive agent is
added in a suitable solvent to form a lipid-bioactive agent complex. In some
embodiments,
the solvent is volatile or dialyzable for convenient removal after addition of
bioactive agent
to the lipid bilayer vesicle dispersion. Following further agitation;
lipidvbinding
polypeptide is added and the sample is incubated, mixed by agitation, and/or
sonicated.
Typically, the vesicles and apolipoprotein are incubated at or near the gel to
liquid
crystalline phase transition temperature of the particular bilayer Forming
lipid or mixture of
bilayer-forming lipids being used. The phase transition temperature may be
determined by
calorimetry.
[0100] Preferably, a suitable bilayer-forming lipid composition is used such
that, upon
dispersion in aqueous media, the lipid vesicles provide a suitable environment
to transition
a bioactive agent from a carrier solvent into an aqueous milieu without
precipitation or
phase separation of the bioactive agent. The pre-formed lipid bilayer vesicles
are also
preferably capable of undergoing lipid binding polypeptide-induced
transformation to form
the delivery particles of the invention. Further, the lipid-bioactive agent
complex preferably
retains properties of the lipid vesicles that permit transformation into
bioactive agent
delivery particles upon incubation with a lipid binding polypeptide under
appropriate
conditions. The unique combination of lipid substrate-bioactive agent complex
organization and lipid binding polypeptide properties combine to create a
system whereby,
under appropriate conditions of pH, ionic strength, temperature, and lipid -
bioactive agent
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
27
-lipid binding polypeptide concentration, a ternary structural reorganization
of these
materials occurs wherein stable lipid binding polypeptide circumscribing lipid
bilayers are
created with a bioactive agent incorporated into the lipid milieu of the
bilayer. For a
discussion of the effect of pH, ionic strength and lipid binding polypeptide
concentration on
the ability of lipid binding polypeptides to induce transformation of
different types of
phospholipid vesicles into disc shaped particles, see Weers et al. (2001) Eur.
J. Biochem.
268:3728-35.
[0101] The particles prepared by any of the above processes may be further
purified, for
example by dialysis, density gradient centrifugation and/or gel permeation
chromatography.
[0102] In a preparation method for formation of bioactive agent delivery
particles,
preferably at least about 70, more preferably at least about 80, even more
preferably at least
about 90, even more preferably at least about 95 percent of the bioactive
agent used in the
procedure is incorporated into the particles.
[0103] The invention provides bioactive agent delivery particles prepared by
any of the
above methods. In one embodiment, the invention provides a pharmaceutical
composition
comprising a delivery particle prepared by any of the above methods and a ,.
pharmaceutically acceptable carrier.
Storage and stability
[0104] Particles of the invention are stable for long periods of time under a
variety of
conditions (see, for example, Fig. 5). Particles, or compositions comprising
particles of the
invention, may be stored at room temperature, refrigerated (e.g., about
4°C), or frozen (e.g.,
about -20°C to about -80°C). They may be stored in solution or
dried (e.g., lyophilized).
Bioactive agent delivery particles may be stored in a lyophilized state under
inert
atmosphere, frozen, or in solution at 4°C. Particles may be stored in a
liquid medium, such
as a buffer (e.g., phosphate or other suitable buffer), or in a carrier, such
as for example a
pharmaceutically acceptable carrier, for use in methods of administration of a
bioactive
agent to an individual. Alternatively, particles may be stored in a dried,
lyophilized form
and then reconstituted in liquid medium prior to use.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
28
Kits
[0105] The reagents and particles described herein can be packaged in kit
form. In one
aspect, the invention provides a kit that includes delivery particles and/or
reagents useful
for preparing delivery particles, in suitable packaging. Kits of the invention
include any of
the following, separately or in combination: lipid binding polypeptides (e.g.,
apolipoproteins), phospholipids, bioactive agents, vectors, reagents, enzymes,
host cells
and/or growth medium for cloning and/or expression of recombinant lipid
binding
polypeptides (e.g., recombinant apolipoproteins) and/or lipid binding
polypeptide chimeras
(e.g., apolipoprotein chimeras), and reagents and/or pharmaceutically
acceptable carriers .
for formulating delivery particles for administration to an individual.
[0106] Each reagent or formulation is supplied in a solid form, liquid buffer,
or
pharmaceutically acceptable carrier that is suitable for inventory storage, or
optionally for
exchange or addition into a reaction, culture, or injectable medium. Suitable
packaging is
provided. . As used herein, "packaging" refers to a solid matrix or material
customarily used
. in a system and capable of holding within fixed limits one or more of the
reagents or
components (e.g., delivery particles) for use in a method for delivery of a
bioactive agent or .
:~ one or more reagents for preparing or formulating delivery particles (e.g.,
apolipoprotein
molecules;:,phospholipids~ bioactive agents). Such materials include, but are
not limited to;
glass and plastic (e.g., polyethylene, polypropylene, and polycarbonate)
bottles, vials,
paper, plastic, and plastic-foil laminated envelopes, and the like.
[0107] A kit may optionally provide additional components that are useful in
the methods
and formulation procedures of the invention, such as buffers, reacting
surfaces, or means of
purifying delivery particles.
[0108] In addition, the kits optionally include labeling and/or instructional
or interpretive
materials providing directions (i. e., protocols) for the practice of the
methods of this
invention, such as preparation, formulation and/or use of delivery particles.
While the
instructional materials typically comprise written or printed materials they
are not limited
to these formats. Any medium capable of storing such instructions and
communicating
them to an end user is contemplated by this invention. Such media include, but
are not
limited to electronic storage media (e.g., magnetic discs, tapes, cartridges,
chips), optical
media (e.g., CD ROM), and the like. Such media may include addresses to
Internet sites
that provide such instructional materials.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
29
[0109] The following examples are intended to illustrate but not limit the
invention.
EXAMPLES
Example 1 Preparation and Characterization of ApoA-I-Phospholipid-Amphotericin
B Particles
Preparation ofRecombinantApoA I
[0110] Recombinant Apo-A-I was prepared as described in Ryan et al. (2003)
Protein
Expression and Purification 27:98-103, and was used to prepare Apo-A-I-
phospholipid-
AmB particles, as described below.
Preparation ofApoA I phospholipid AmB particles
[0111] ApoA-I-phospholipid-AmB particles were prepared as follows:
[0112] A 7:3 molar ratio of dimyristoylphosphatidylcholine (DMPC) and
dimyristoylphosphatidylglycerol (DMPG) were dissolved in chloroform:methanol
(3:1,
v/v). .To 10 mg of the DMPC/DMPG mixture, 0.25 ml of AmB (2 mg/ml; solubilized
in
acidified chloroform:methanol (3:1, v/v)) was added. The mixture was dried
under a
stream of N2 gas to create a thin film on the vessel wall. The dried sample
was then
subjected to lyophilization for sixteen hours to remove traces of solvent.
(0113] The dried lipid mixture was resuspended in 0.5 ml Tris-Saline buffer
(10 mM Tris
base 150 mM NaCI, pH 8), and the mixture was vortexed for 30 seconds.
[0114] To the resuspended lipid mixture, 0.5 ml of 22 mM sodium cholate was
added to
the mixture and vortexed for 3 minutes. This mixture was incubated at
37°C with
vortexing every 10 minutes for 1.25 hours or until the mixture was clear. To
the cleared
solution, 2 ml of isolated recombinant ApoA-I, prepared as described in
Example 1, was
added at a concentration of 1.5 mg/ml, and the mixture was incubated at
37°C for an
additional 1 hour. To remove sodium cholate, the sample was subjected to
dialysis against
4 liters of Tris-Saline at 4°C for 72 hours with a change of dialysis
buffer every 24 hours.
[0115] The sample was fiuther purified by density gradient
ultracentrifugation. The
solution was adjusted to a density of 1.30 g/ml by the addition of solid KBr
in 1.5 ml. The
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
sample was transferred to a 3 ml centrifuge tube, overlayered with saline and
centrifuged at
275,000 x g for 3 hours in a Beckman L7-55 centrifuge.
Particle Stability
[0116] The particles prepared according to this procedure were stable for more
than 3
months in lyophilized form.
Characterizatioft of Particles
[0117] UV/visible scans were performed for ApoA-I-phospholipid particles,
prepared as
described above but without the addition of AmB, and were compared with scans
for the
AmB-containing particles. Fig. l shows the scan for particles that do not
include AmB.
The only peak observed was a protein peak at around 280 run. Fig. 2 shows the
scan for
AmB-containing particles prepared as described above. In addition to the peak
at around
280 nm, a number of additional peaks were observed in the 300-400 nm region of
the
spectrum, confirming the presence of AmB. Free AmB is insoluble in aqueous
media and
has different spectral properties than observed in Fig. 2. Madden et al.
(1990) Chemistry
and Physics of Lipids, 52:189-98.
[0118] Characterization studies revealed that the ApoA=I; phospholipid, and
AmB
migrate as a discrete particle population when subjected to density gradient .
ultracentrifugation (Fig. 3). The complexes float to a characteristic density
in the gradient
that is dependent upon the protein/lipid ratio in the particles.
[0119] Further, gradient gel electrophoresis under non-denaturing conditions
revealed
that the major complex generated is of uniform size, displaying a Stokes'
diameter of 8.5
nm (Fig. 4). Analysis of the isolated particles revealed that significant
deviation from the
original molar ratios of AmB, phospholipid, and apolipoprotein did not occur.
Example 2 Antifun~al Activity of AmB Containing Bioactive Agent Delivery
Particles against Saccharomyces cerevisiae
[0120] ApoA-I-DMPC/DMPG-AmB particles were prepared as described in Example 1
and used to determine antifungal activity of the complexes. Cultures of S.
cerevisiae were
grown in YPD medium in the presence of varying amounts of ApoA-I-DMPC/DMPG-
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
31
AmB particles (0-25 ~,g AmB/ml). The cultures were grown for 16 hours at
30°C, and the
extent of culture growth monitored spectrophotometrically. As shown in Fig. 8,
the AmB-
containing particles were extremely effective in inhibiting fungal growth in a
dose-
dependent manner.
Example 3. Long Term Stability of Bioactive Agent Delivery Particles
[0121] Recombinant ApoE3NT-terminal domain (ApoE3NT) was prepared as in Fisher
et al. (1997) Biochem Cell Biol 75:45-53. ApoE3NT-AmB-containing particles
were
prepared via the cholate dialysis method described in Example l, and used to
assess long-
term stability.
[0122] Fig. 5 shows a native PAGE 4-20% gradient slab gel of particles stored
in
phosphate buffer at 4°C (lane 1), stored in phosphate buffer at -
20°C (lane 2), or frozen in
phosphate buffer at -80°C, lyophilized, and redissolved in H20 prior to
analysis: The size
and mobility of the AmB-containing particles were unaffected by freezing and
thawing, or
by lyophilization and resolubilization, indicating that the particles retained
their integrity .°
under these conditions. These are important parameters with regard to scale up
and long-
term storage of AmB delivery particles.
Example 4. Preparation of AmB-Containing Bioactive Agent Delivery Particles
with
POPC
[0123] ApoA-I-POPC particles were prepared using the cholate dialysis method
described in Example 1. A native PAGE gradient gel analysis of ApoA-I-POPC
particles is
shown in Fig. 4. Particles without AmB are shown in lane l and particles with
AmB are
shown in lane 2. The gel indicates that incorporation of AmB into the
particles does not
alter their size. However, the gel indicates that the POPC containing
particles are a
different size than DMPC/DMPG particles, shown in lane 3.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
32
Example 5 Preparation of AmB-containing Particles with a Microfluidizer
Processor
[0124] ApoA-I, AmB, egg PC, DPPG, and cholesterol were combined in a
microfluidizer
sample holder and passed through the reaction chamber of microfluidizer
processor at
18,000 psi. The resultant~solution was collected and characterized in terms of
particle
formation, incorporation of hydrophobic substances, size, and stability. AmB-
containing
particles of about 16 nm diameter were obtained, which were stable to
lyophilization and
aqueous solvent reconstitution.
Example 6 Preparation of AmB-containing Particles from Phospholipid Vesicles
[0125] A suspension of AmB-containing phospholipid vesicles was prepared by
adding
an aliquot of a 20-40 mg/ml solution of AmB in DMSO, corresponding to 2.5 mg
AmB, to
a preformed phospholipid aqueous dispersion containing a molar ratio of 7:3
DMPC:DMPG. The vesicles were incubated at the gel to liquid phase transition
temperature of the phospholipids (about 24° C). Addition of 4
mgapolipoprotein °led to a
time-dependent decrease in sample turbidity, consistent with formation of AmB-
containing
bioactive agent delivery particles. Full sample clarity was achieved by mild
bath sonication
at 21-25°C for 1-20 minutes or in 4-16 hours without sonication at
24°C. The resulting
particles exhibited >90% AmB incorporation efficiency, i. e., the percentage
of AmB
starting material that is recovered in delivery particles, and no material was
lost upon
filtration, centrifugation, or dialysis. Other tests revealed that similar
results can be
achieved with AmB concentration adjusted to as high as 5 mg/10 mg
phospholipid. This
procedure worked equally well with any of five apolipoproteins tested (ApoA-I,
ApoE3NT,
Bombyx mori~ApoIII, and a variant form of human ApoA-I that includes a C-
terminal
extension including the antifungal peptide, Histatin 5, and a variant form of
human ApoA-I
that includes a C-terminal extension including the S cerevisiae a-mating
factor peptide).
[0126] Density gradient ultracentrifugation of ApoA-I or ApoE3NT containing
particles
revealed a single population of particles that floated to a characteristic
density in the range
of 1.21 g/ml, consistent with formation of lipid-protein complexes.
Characterization of the
fractions obtained following density gradient ultracentrifugation revealed
that
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
33
phospholipid, AmB, and apolipoprotein migrated to the same position in the
gradient,
consistent with formation of AmB-containing particles.
[0127] Comparison of the relative migration of ApoA-I-AmB-containing particles
with
known standards on native PAGE indicated that over 90% of the particles had a
Stokes'
diameter of approximately 8.5 nm. This value is similar to particles generated
in the
absence of AmB, indicating that addition of this bioactive agent did not
significantly alter
the size distribution of the particles.
[0128] As a measure of the overall stability of the ApoA-I-AmB-containing
bioactive
agent delivery particles, the particles were frozen at -20°C or
lyophilized.
Freezing/thawing had no effect on the size distribution of the particles.
Likewise,
subjecting the particles to lyophilization and re-dissolving in H20 did not
affect the size
distribution or sample appearance.
[0129] These data strongly suggest that AmB, phospholipids, and apolipoprotein
combined to form a homogeneous population of bioactive agent delivery
particles in which
AmB is fully integrated into the bilayer portion of the particle.
Spectrophotometric
analysis of the AmB-containing particles revealed a characteristic set of
peaks in the visible
range that are consistent with AmB solubilization in the bioactive agent
delivery panicle.
Example 7. Comparison of AmB-containing Particles Prepared as in Example 6
with
Particles Prepared by an Alternate Procedure
[0130] Incorporation of bioactive agent into bioactive agent delivery
particles using the
method described in Example 6 was compared with incorporation into "neo-HDL"
particles
prepared according to Schouten et al. (1993) Molecular Pharmacology 44:486-
492, as
follows: Three mg of egg yolk phosphatidylcholine, 0. 9 mg cholesterol, and 1.5
mg AmB,
dissolved in chloroform, were mixed in a 20 ml glass vial, and the solvent was
evaporated
under a stream of nitrogen. Ten ml of sonication buffer (10 mM Tris HCI, pH
8.0, 100 mM
KCI, 1 mM EDTA, and 0.025% NaN3), degassed and saturated with nitrogen, were
added
and the contents of the vial sonicated with a Macrotip (14 ~m average output)
under a
stream of nitrogen. The temperature was maintained above 41°C and below
50°C. The
sonication was stopped after 60 minutes, and the temperature adjusted to
42°C. Sonication
was continued and 20 mg of ApoA-I, dissolved in 2 ml of 4M urea, was added in
ten equal
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
34
portions over a period of 10 minutes. After all of the protein was added,
sonication was
continued for 30 min at 42°C.
[0131] The sonication mixture was then centrifuged for 3 minutes to remove
large
particles and insoluble material and the supernatant analyzed by UV/Visible
spectrophotometry to assess the amount of amphotericin B solubilized in the
product
particles. It was noted that the solution was slightly opaque. The sample was
scanned from
250 nm to 500 nm. For comparison, AmB-containing particles prepared by the
procedure
described in Example 6 were examined. The results are shown in Fig. 12. The
region of
the spectrum arising from AmB (300-500 nm) is quite distinct between the two
samples.
Whereas AmB-containing bioactive agent delivery particles generated using the
protocol
described in Example 6 had strong characteristic absorbance maxima that
indicate
solubilization and incorporation of AmB into the particles (Madden et al.,
supra) (Fig.
12B), the sample prepared according to Schouten et al. did not give rise to
these
characteristic spectral maxima (Fig. 12A). Indeed, the spectrum obtained is
very similar to
that reported by Madden et al., supra, for an aqueous dispersion of AmB in the
absence of
lipid. Thus, AmB was not incorporated into lipid particles using this
procedure, whereas
the procedure described in Example 6 resulted in significant AmB
incorporation.
Example 8. Comparison of Anti-Fungal Activity of AmB-Containing Bioactive
Agent
Delivery Particles with Liposomal AmB Formulation
[0132] Anti-fungal activity of ApoA-I-AmB particles, prepared as in Example 6,
and a
commercial liposomal formulation of AmB, AmBisome~, were compared with respect
to
their ability to inhibit the growth of the yeast, S cerevisiae. The data in
Fig.10 show that
ApoA-I-AmB bioactive agent delivery particles more effectively inhibited S
cerevisiae
growth than the same amount of AmB formulated as AmBisome~. ApoA-I-AmB
bioactive
agent delivery particles achieved 90% growth inhibition at 1 ~,g/ml, whereas
this level of
inhibition required 25 ~.g/ml AmBisome~.
[0133] Anti-fungal activity of ApoA-I-AmB particles and AmBisome~ were also
compared against two species of pathogenic fungi, Cahdida albicans (C.
albicans) and
Aspergillus fumigatus (A. fumigatus), in microtiter broth whole-cell assays.
As a control,
particles without AmB were also tested. The results are shown in Table 1.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
Table 1
Amphotericin B Inhibition of Pathogenic Fungal Growth
ED9o (p,g/ml)
Organism AmBisome Delivery Control
particlesparticles
with AmB without AmB
Caudida albicans 0.8 0.1 No inhibition
Aspergillus fumigatus1.6 0.2 No inhibition
[0134] The results ~btained revealed that AmB-containing bioactive agent
delivery
particles were effective against both pathogenic fungal species, at a lower
concentration
than AmBisome~. Control particles lacking AmB were not effective. AmB-
containing
bioactive agent delivery particles exhibited an ED9o (concentration at which
90% growth
inhibition is observed) for C. albicans at a concentration of 0.1 ~,g/ml,
whereas 0.8 ~g/ml
AmBisome was required to achieve the same level V~of growth inhibition. For A.
fumigatus, AmB-containing bioactive agent delivery particles inhibited 90% of
fungal
growth at a concentration of 0.2~,g/ml, whereas 1.6 ~,g/ml AmBisome~ was
required to
achieve the same effect.
[0135] In another experiment, AmB-containing bioactive agent delivery
particles
containing apolipophorin III as the lipid-binding polypeptide were compared
with
~_AmBisome~ for their ability to inhibit growth of three species of pathogenic
fungi, C.
albicaus, A. fumigatus, and Cryptococcus neofo~mans (C. heoformahs). The data
are
shown in Table 2.
Table 2
Amphotericin B Inhibition of Pathogenic Fungal Growth
ED9o (~,g/ml)
Organism ~ AmBisome ~ Delivery ~ Control
particles ~ particles
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
36
with AmB without AmB
Cahdida albica~s 0.4 0.03 No inhibition
Aspergillus fumigates2.5 0.1 No inhibition
Cryptococcus neoformaus0.31 0.06 No inhibition
[0136] AmB-containing bioactive agent delivery particles inhibited 90% of C.
albica~cs
growth at 0.03 p,g/ml. A corresponding ED9o of 0.4 ~,glml was obtained with
AmBisome~.
In the case of A. fumigates, AmB-containing bioactive agent delivery particles
inhibited
90% of fungal growth at 0.1 ~,g/ml, whereas a concentration of 2.5 ~,glml
AmBisome~ was
required to achieve the same effect. In a similar manner, AmB-containing
particles were
effective at inhibiting C. neoformahs growth at a five-fold lower AmB
concentration than
AmBisome~.
[0137] All samples tested were soluble in the RPMI media used for the
experiments and
no precipitation or interference was observed in any of the samples tested
against any of the
fugal species. These data suggest that a formulation of AmB in the bioactive
agent
delivery particles of the invention has more potent anti-fungal activity than
a liposomal
formulation.
Example 9. Incorporation of Camptothecin into Bioactive Agent Delivery
Particles
[0138] Camptothecin-containing bioactive agent delivery particles were
prepared as
follows: A 7:3 molar ratio of DMPC:DMPG (5 mg total) was dispersed in buffer
(20 mM
sodium phosphate, pH 7.0) by vortexing for 1 minute to generate a dispersion
of
phospholipid bilayer vesicles. Ten microliters of a 10 mg/ml solution of
camptothecin in
DMSO was added to the phospholipid bilayer dispersion. Two mg of recombinant
human
apolipoprotein A-I (0.5 ml of a 4 mg/ml solution in 20 mM sodium phosphate, pH
7.0) was
then added, and the sample was then subjected to sonication. The clarified
sample was
then centrifuged at 13,000 x g for 3 minutes and the supernatant recovered and
stored at 4°
C.
[0139] A fluorescence spectrum of the camptothecin-containing particles, in
comparison
with sodium dodecyl sulfate (SDS) solubilized camptothecin, is shown in Fig.
ll.
Fluorescence measurements were obtained on a Perkin Elmer LS SOB luminescence
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
37
spectrometer at an excitation wavelength of 360 nm with,emission monitored
from 400 to
600 nm. The blue shift in fluorescence emission maximum elicited by
camptothecin in
SDS micelles (Fig. 11A) compared to camptothecin incorporated into bioactive
agent
delivery particles (Fig. 11B) suggests that the drug localizes to a more
hydrophobic
environment in the micelles versus the delivery particles.
Examule 10. Freeze Fracture Electron Microscopy of AmB-containing Bioactive
Agent Delivery Particles
[0140] A preparation of AmB-containing bioactive agent delivery particles was
prepared .
for freeze fracture electron microscopy as follows: A sample of DMPC:DMPG (7:3
molar
ratio) AmB bioactive agent delivery particles (3 mg/ml protein), prepared as
in Example 6,
was quenched using a sandwich technique, and liquid nitrogen cooled propane.
The cryo-
fixed sample was stored in liquid nitrogen for less than 2 hours prior to
processing. The
fracturing process was carried out in JOEL JED-900 freeze-etching equipment
and the
exposed fracture planes were shadowed with Pt for 30 seconds at an angle of 25-
35
degrees, and with carbon for 35 seconds (2 kV/60-~0 mA, 1 x 10-5 Torr). The
replicas
produced in this way were cleaned with concentrated Earning HN03 for 24 hours
followed
by repeated agitation with fresh chloroform/methanol (l :l by volume) at least
5 times. The
replicas cleaned in this way were examined on a JOEL 100 CX or a Philips CM 10
electron
microscope.
[0141] An electron micrograph obtained from freeze fracture of AmB-containing
particles as described above is shown in Fig. 9. Electron micrographs taken
from several
freeze-fracture preparations indicate the presence of small protein-lipid
complexes in high
concentration. The apparent diameters range from about 20-60 nm with high
frequency
around 40 nm. The apparent diameter of particles as observed by freeze
fracture electron
microscopy is larger than values obtained by native pore limiting gradient gel
electrophoresis. The difference may be due to the effect of sample handling or
the staining
procedure used to visualize the particles by electron microscopy.
[0142] The substantially spherical complexes do not display concave or convex
fracture
faces (shadow in front and behind the structure, respectively), as are
characteristic for
liposomes. Further, no evidence for micellar structures was observed.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
38
Example 11. In vivo Assessment of Anti-fungal Activity of AmB-containing
Bioactive
A~Pnt Delivery Particles in Immunocompetent Mice
[0143] ~n vivo anti-fungal activity of AmB-containing bioactive agent delivery
particles
is assessed as follows:
Animals
[0144] Six to eight-week-old female BALB/c mice (20-25g) are housed and
maintained
under standard laboratory conditions.
Toxicity study
[0145] Groups of three mice each receive a dose (e.g., 1, 2, 5, 10, or 15
mg/kg AmB) in
AmB-containing bioactive agent delivery particles, or control particles
without AmB, in
saline buffered to pH 7.4 with 10 mM sodium phosphate. A single dose is
administered as
a 0.1 ml volume intraperitoneally. Preliminary studies have indicated that the
bioactive
agent delivery particles are fully soluble under these conditions. .
[0146] Following injection, the mice are observed for any general reaction,
for example,
abnormal movement or posture, difficulty in breathing, ruffled fur, or
inability to obtain
food or drink. Observation for abnormality or mortality begins immediately
after
administration and continues twice daily for seven days. Body weight is
recorded daily for
the same period.
[0147] Blood is collected from mice prior to euthanization. The blood is
assayed for
liver enzymes such as lactate dehydrogenase to assess the degree of liver
specific damage
Efficacy ofAmB-containing bioactive agent delivery particles in treatment of
systemic
cryptococcus
(0148] The therapeutic range of AmB-containing particles is determined and
compared
with AmBisome~ as follows:
[0149] A clinical isolate of C. neofor~rnans that is susceptible to AmB is
cultured and
prepared as an inoculum for infection at a concentration of 2 x 106
conidia/ml. Each mouse
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
39
receives an inoculum of 1 x 105 conidia in 0.05 ml of normal saline
intracranially under
general anesthesia.
[0150] Anti-fungal agents are administered intraperitoneally in 0.1 ml volumes
daily for
days, starting 2 hours post-infection. The dosage of AmB used is determined
based on
the toxicity studies described above. One treatment group of mice receives
AmBisome~,
one treatment group receives AmB-containing bioactive agent delivery
particles, and a
control group receives no therapy.
[0151] Infected mice are monitored twice daily and any signs of illness or
mortality is
recorded for up to 28 days. Body weight is recorded daily for the same time
period.
Moribund animals that fail to move normally or take food or drink are
euthanized. Based
on the outcome of these studies, a sec~nd set of studies is performed to
verify and
reproduce the findings. The AmB dose employed, as well as the number of mice
in the
control and treatment groups, may be adjusted to reflect knowledge gained from
the
previous experiment.
Determination of tissue fungal burden
[0152] Mice are sacrificed one day after the last day of treatment. The
kidneys and
brains are removed aseptically and weighed. Tissues are homogenized and
serially diluted
in normal saline. The homogenates are cultured for 48 hours on PDA (potato
dextrose
agar) plates to determine the colony forming units (CFU). Fungal burden of
CFUlgram of
tissue is determined.
Statistical analyses
[0153] Differences in survival and mean CFUs in kidney or brain are compared
using
statistical tests as appropriate.
Pharmacokinetic study
[0154] Blood, liver, kidney, lung, and cerebrospinal fluid samples are
collected from
infected mice at time points of 10 minutes, 2, 8, and 24 hours after
intravenous injection of
AmB bioactive agent delivery particles or AmBisome~ at 0.8 and 2.0 mg/kg
doses. While
mice are under general anesthesia, whole blood is collected from axillary
vessels. A
thoracotomoy is performed, and tissue samples perfused with normal saline and
then
removed surgically. Tissues are homogenized with methanol containing 1-amino-4-
nitronaphthalene. Serum and the supernatants of tissue homogenates are
preserved until
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
analysis. The concentration of AmB in each sample is determined by high-
performance
liquid chromatography (HPLC), as described in Granich et al. (1986)
A~ctimic~ob. Agents
Chemothe~. 29:584-88. Briefly, serum samples (0.1 ml) are combined with 1.0 ml
methanol containing 1.0 mg of an internal standard, 1-amino-4-
nitronaphthalene, per ml
and mixed by vortexing. After centrifugation, the supernatant is dried under
reduced
pressure followed by redissolving with 0.2 ml of methanol for injection onto a
HPLC
column (C1$ reverse phase). Weighed wet tissue samples are homogenized in 10
volumes
of methanol containing 5.0 mg internal standard per ml with a glass
homogenizer and
centrifuged. The mobile phase is a mixture of acetonitrile and 10 mM sodium
acetate
buffer (pH 4.0; 11:17 (vol/vol)), at'a flow rate of 1.0 ml/min. The
concentration of AmB is
determined by the ratio of the peak height of AmB to that of the internal
standard.
Example 12. Tar~etin~ of Camptothecin-containing Bioactive Agent Delivery
Particles to Tumor Cells
[0155] Bioactive agent. delivery agent particles are prepared with a VIP
targeting moiety
attached to the lipid binding polypeptide component.
[0156] The lipid binding polypeptide component of the camptothecin-containing
particles
may be generated in recombinant form in Escherichia coli (E. coli) that have
been
transformed with a plasmid vector harboring the coding sequence of the lipid
binding
polypeptide. For example, recombinant human ApoA-I may be employed. E. coli
cells
harboring an ApoA-I expression plasmid are cultured in media at 37 °C.
When the optical
density of the culture at 600 nm reaches 0.6, ApoA-I synthesis is induced by
the addition of
isopropylthiogalactoside (0.5 mM final concentration). After a'fi~rther 3
hours of culture,
the bacteria are pelleted by centrifugation and disrupted by sonication. The
cell lysate is
centrifuged at 20,000 x g for 30 min at 4 °C and apoA-I isolated from
the supernatant
fraction.
[0157] A recombinant lipid binding polypeptide chimera is produced by
engineering
ApoA-I to include an N-terminal and/or C-terminal peptide extension that
corresponds to
the 28 amino acid neuropeptide, vasoactive intestinal peptide (VIP). ApoA-I-
VIP chimeras
may be employed to create bioactive agent delivery particles comprised of
phospholipid,
camptothecin and ApooA-I-VIP chimera.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
41
[0158] For example, an ApoA-I-VIP chimera may be constructed by synthesizing
complementary oligonucleotide primers corresponding to the coding sequence of
the VIP
sequence possessing terminal Hind III and Xba I sites. The oligonucleotides
0100 base
pairs) are annealed to generate double stranded DNA with the desired "sticky
ends" and
subcloned into the ApoA-I coding sequence-containing plasmid vector that has
appropriately placed Hind III and ~ba I restriction enzyme sites. Following
ligation,
transformation and screening for a positive chimera construct, the plasmid DNA
is isolated
and subject to automated dideoxy chain termination sequence analysis.
Following
confirmation that the sequence corresponds to that predicted for the desired
chimera,
production of recombinant ApoA-I-VIP chimera is performed in E. coli, as
described above
for wild type ApoA-I. Purified recombinant chimera is then evaluated by gel
electrophoresis, mass spectrometry and for its ability to generate bioactive
agent delivery
particles of the invention in a manner similar to wild type ApoA-I, as
described in Example
8. ,
[0159] ApoA-I-VIP chimera-camptothecin-containing bioactive agent delivery
particles
may be used in breast cancer cell growth inhibition studies to measure the
extent of lipid
particle targeting. For example, the human breast cancer cell line MCF-7 is
obtained from'
the American Type Culture Collection and maintained at 37°C in a
humidified 5% COZ
incubator as monolayer cultures in modified Eagle's.media supplemented with
10% fetal
bovine serum and the antibiotics penicillin and streptomycin. Isolated wild
type ApoA-I or
ApoA-I-VIP chimera is radioiodinated and incorporated into camptothecin-
containing
bioactive agent delivery particles of the invention and incubated with the
cells. Cell-
associated radioactivity is determined after incubation of labeled
camptothecin-containing
bioactive agent delivery particles with cultured MCF-7 cells at 4 °C.
The ability of VIP to
compete for binding of ApoA-I-VIP chimera or bioactive agent delivery particle-
associated
ApoA-I-VIP chimera to MCF cells is determined in competition binding assays.
Cell
binding data is evaluated by Scatchard analysis. The extent of MCF-7 cell
internalization of
ApoA-I-VIP chimera bioactive agent delivery particles is evaluated in
incubations with
radioiodinated ApoA-I-VIP chimera-containing bioactive agent delivery
particles at 37 °C.
After incubation and washing, trichloroacetic acid soluble radioactivity is
determined,
providing a measure of lipid binding polypeptide degradation.
[0160] Growth inhibition and cytotoxicity studies with different bioactive
agent delivery
particles are assessed by clonogenic assay. Exponentially growing cells are
resuspended in
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
42
media and cell number determined using an electronic counter. Alternatively,
camptothecin-ApoA-I-VIP chimera bioactive agent delivery particle inhibition
of MCF-7
clonal growth may be evaluated on the basis of reduced 35S-methionine uptake.
Aliquots of
cells are inoculated in triplicate into culture dishes. After incubation,
specific lipid particles
are added from a stock solution to the dishes to achieve final concentrations
of 0, 0.1, l, 5,
10, 50, 100, and 250 nM camptothecin. After specific time intervals ranging
from 0 to 72
hours, medium is removed by aspiration and fresh medium added. The percentage
survival
at each drug concentration with different exposure times is determined from
the ratio of the
number of Trypan Blue excluding cells and compared to results obtained with
control
particles lacking camptothecin.
Example 13. In vivo Assessment of Toxicity of AmB-containing Bioactive Agent
Delivery Particles
[0161] A study was performed to determine safety and toxicity of AmB-
containing
bioactive agent delivery particles. The particles were prepared as in Example
6.
[0162] Female BAL'B/c mice (6-8 weeks old, 20-25 grams in weight) were divided
into
groups of 3 mice and each group was treated with 1, 2, 5, 10, or 15 mg/kg AmB
formulated
in bioactive agent delivery particles and delivered as a single dose in a 0.1
ml volume in :.
phosphate buffered saline (PBS) intraperitoneally (IP). A control group
received only PBS.
[0163] Mice were observed immediately, 2 hours, and 6 hours post-
administration and at
least twice daily for 7 days thereafter for weight loss or abnormalities in
appearance and
behavior. Blood was drawn 24 hours after administration. Markers for liver
damage
(alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and
kidney
damage (urea and creatinine) were quantified.
[0164] Table 3 below shows the in vivo safety/toxicity profile of bioactive
agent delivery
particles containing AmB.
Table 3
Toxicity of AmB-containing Bioactive Agent Delivery Particles in Mice
AmB Dosage Toxicity Survival % Weight Loss
(mfg) Observations'
15 Toxic 1/3 5.08
Not toxic 3/3 1.59
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
43
Not toxic 3/3 No loss
2 Not toxic 3/3 No loss
1 Not toxic 3/3 No loss
0 Not toxic 313 No loss
(PBS control)
Highly toxic: Dies immediately, or showed signs of toxicity, e.g.,
restlessness, tremor, difficulty in
breathing, poor motor activity, staggering gait, etc. Toxic: Delayed death or
restlessness, poor motor activity,
etc. for about 30 min followed by complete recovery. Little toxic: Few signs
of toxicity (not severe) for a
short period (a few minutes or so).
[0165] A dosage of 15 mg/kg was found to be toxic in mice. At this dosage
level, there
were no immediate deaths or abnormalities but 2 out of 3 mice died the day
following
administration. AmB-containing particles at doses of 10 mglkg or less were
found to be
safe. As shown in Fig.14, nominal weight loss was observed at dosages of 5
mg/kg and
below. In mice treated with 10 mg/kg, significant weight loss was observed on
day two
with subsequent recovery of up to 90% of body weight by the end of the week.
At this
concentration of drug, modest signs of nephrotoxicity (0.16 mg/dl creatinine
at 10 mg/kg
versus 0.1 mg/dl at 0 mg/kg; no change in urea) and no hepatotoxicity was
observed. This
result marks a dramatic decrease in toxicity, since previously-reported
experiments resulted
in only a 4% survival rate for mice at 4.4 mg/kg AmB under similar
experimental
conditions where the AmB was formulated in detergent micelles (Baxwicz et al.
(1992)
A~ctimicrob Agents Chemother 36:2310-2315).
Example 14. In vivo Efficacy of AmB-containing Bioactive Agent Delivery
Particles
[0166] An experiment was performed to determine whether formulating AmB into
bioactive agent delivery particles compromises its anti-fungal effectiveness.
[0167] Female BALB/c mice (6-8 weeks old) were divided into 4 groups of 10
mice
each. Each mouse was inoculated with 5 x 105 blastospores of Candida albicans
ATCC
strain 90028. Two hour's after inoculation, mice were treated with
Fluconazole, an orally-
administrable anti-fungal treatment (30 mg/leg via oral gavage), AmBisome (5
mg/kg IP),
AmB-containing bioactive agent delivery particles (5 mg/kg IP) formulated as
described in
Example 13, or control "empty" bioactive agent delivery particles without AmB
but with
an equivalent protein load to the particles containing AmB. Treatment was
continued once
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
44
a day for 5 days. Throughout the study, mice were monitored for mortality and
abnormalities in appearance and behavior. 24 hours after the last treatment,
mice were
sacrificed and kidney and brain tissues were excised for assessment of fungal
burden. For
survival evaluation, mice were observed for 29 days and examined twice daily
for
mortality, weight loss, and failure to ingest food or water.
[0168] As shown in Fig.16, all mice treated with Fluconazole survived the term
of the
study. One mouse treated with AmB-containing bioactive agent delivery
particles died on
day 2 of the study. Due to the timing of this mouse's death and the absence of
toxicity
related to the AmB-containing particles at 5 mg/kg (see Example 13, above), it
is unlikely
that mortality was related to efficacy of the particles. Conversely, all mice
treated with
"empty" disc particles died and only one of the AmBisome treated mice
survived.
[0169] As shown in Fig.17, mice treated with AmB-containing bioactive agent
delivery
particles exhibited only nominal weight loss (<2%) over the course of the
study.
Conversely, Fluconazole and AmBisome treated mice exhibited a maximum weight
loss of
14% and 23%, respectively, during the course of the experiment.
[0170] As shown in Fig. 18, assessment of fungal burden revealed low fungal
levels in
the brain'and kidney of mice treated with AinB-containing bioactive agent
delivery
particles.: . With the exception of the brain for Fluconazole treated mice,
treatment with
AmB-containing particles resulted in the lowest levels of brain and kidney
fungal burden
among the different treatment regimens.
[0171] The results of this study demonstrate that AmB-containing bioactive
agent
delivery particles are an effective anti-fungal treatment. The mortality rate
observed with
AmBisome treatment was higher than in previously-reported studies using
similar regimens
for treatment of Cryptococcosis infection, where >90% survival rate has been
observed
(Clemons and Stevens (1998) Antimicrob Agents Chemother 42:899-902). However,
Candida albicans treatment may be complicated by the fact that the efficacy of
AmBisome
is dependent on the level of infection at the time of treatment (van Etten et
al. (1998)
Antimicrob Agents Chemother 42:2431-2433). The inoculum used in this study may
represent a level of fungal burden beyond the capability of AmBisome to
effectively treat,
whereas the efficacy of AmB-containing disc particles was not affected by this
level of
infection.
CA 02541117 2006-03-31
WO 2005/039534 PCT/US2004/025412
[0172] Although the foregoing invention has been described in some detail by
way of
illustration and examples for purposes of clarity of understanding, it will be
apparent to
those skilled in the art that certain changes and modifications may be
practiced without
departing from the spirit and scope of the invention. Therefore, the
description should not
be construed as limiting the scope of the invention, which is delineated by
the appended
claims.
[0173] All publications, patents, and patent applications cited herein are
hereby
incorporated by reference in their entirety for all purposes and to the same
extent as if each
individual publication, patent, or patent application were specifically and
individually
indicated to be so incorporated by reference.
